US Elections: Republican Sweep Would Ease Path For Biopharma Policy Priorities

 
• By Cathy Kelly

While election results are not complete, prospects improve under new regime for 340B program reforms, PBM legislation, and Inflation Reduction Act drug pricing revisions. But immediate priorities for Congress and the new president will be elsewhere.

Republicans are all smiles. Industry probably is too. (Shutterstock)

More from Drug Pricing

More from Scrip